Showing results (1011-1020 of 1,073) with videos related to

Sort By:
Pageof 108
Hepatology (Baltimore, Md.)|October 27, 2019
RNA Interference Therapy With ARC-520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B InfectionMan-Fung Yuen, Ingolf Schiefke, Jung-Hwan Yoon, et al.
Oncology Nursing Forum|August 25, 2015
The 2014-2018 Oncology Nursing Society Research AgendaM Tish Knobf, Mary E Cooley, Sonia Duffy, et al.
Journal of Autism and Developmental Disorders|August 22, 2025
The Effect of Different Algorithms on Prevalence of Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder in Secondary Healthcare Data in Five European Countries: A Contribution from the ConcePTION ProjectJoanne Given, Olga Paoletti, Rebecca Bromley, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|February 20, 2021
Targeted delivery of mycophenolic acid to the mesenteric lymph node using a triglyceride mimetic prodrug approach enhances gut-specific immunomodulation in miceRuby Kochappan, Enyuan Cao, Sifei Han, et al.
The Lancet. Oncology|October 4, 2019
Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 studyNeeraj Agarwal, Kelly McQuarrie, Anders Bjartell, et al.
British Journal of Clinical Pharmacology|June 30, 2016
EUROmediCAT signal detection: a systematic method for identifying potential teratogenic medicationJohannes M Luteijn, Joan K Morris, Ester Garne, et al.
Future Oncology (London, England)|December 21, 2023
Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a plain language summary of the TITAN studySimon Chowdhury, Anders Bjartell, Neeraj Agarwal, et al.
The New England Journal of Medicine|June 1, 2019
Apalutamide for Metastatic, Castration-Sensitive Prostate CancerKim N Chi, Neeraj Agarwal, Anders Bjartell, et al.
Archives of Disease in Childhood|February 19, 2024
Hospital care in the first 10 years of life of children with congenital anomalies in six European countries: data from the EUROlinkCAT cohort linkage studyJoan K Morris, Maria Loane, Charlotte Wahlich, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 2023
Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancerS Chowdhury, A Bjartell, N Agarwal, et al.
Pageof 108